Lung Cancer | Norton Healthcare

Indication: Lung Cancer

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Sub-indication: Lung Cancer

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: AbbVie

Learn more at ClinicalTrials.gov

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.